Registry update — unassessed
Targeting mTOR With Everolimus and/or Physical Training for Preventing Postmenopausal Bone Loss and Accelerated Skeletal Aging: The RapaLoad Study
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTN=136Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 7, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No results are reported, so the study cannot be evaluated for whether the interventions prevent bone loss or other skeletal outcomes in postmenopausal women.
- The abstract provides only the study protocol and design; actual efficacy or safety findings are not presented.
- The timing and completion status of this trial are unclear from the material provided, leaving uncertainty about whether results are pending or unavailable.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 136
- Duration
- 6 months
- Population
- Healthy postmenopausal women aged 45-60 years with T-score >-3 and no history of hip, Colles' or symptomatic vertebral fractures within the last 6 months
- Primary outcome
- Percentage change in bone formation marker P1NP (Procollagen Type 1 propeptide) between baseline and week 24
- Effect size
- —
- Significance
- Not reported
- Journal
- Odense University Hospital
- Published
- Apr 7, 2026
Sources
Primary source
- Odense University Hospital ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The trial will include 136 women aged 45-60 years with T-score >-3 and no history of hip, Colles' or symptomatic vertebral fractures within the last 6 months, randomized to 24 weeks of treatment
The primary outcome of this trial is percentage change in bone formation marker P1NP (Procollagen Type 1 propeptide) between baseline and week 24
Secondary outcomes include percentage changes in bone resorption marker CTX (cross-lined C-telopeptide of type 1 collagen), bone mineral density (BMD), bone structure as determined by high resolution CT-scanning, muscle function and postural balance
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.